Cargando…
Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial
BACKGROUND: Chemotherapy-related fatigue (CRF) is a common symptom in non-small cell lung cancer (NSCLC) patients. A Chinese herbal formula cream for oral application, called Jianpishengsui (JPSS), is extensively used in the First Affiliated Hospital of Guangzhou University of Chinese Medicine as an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966901/ https://www.ncbi.nlm.nih.gov/pubmed/31948475 http://dx.doi.org/10.1186/s13063-019-3982-3 |
_version_ | 1783488842297245696 |
---|---|
author | Xiao, Zhiwei Hu, Leihao Lin, Jietao Lu, Liming Huang, Xuewu Zhu, Xiaoshu Teo, Chiahshean Lin, Lizhu |
author_facet | Xiao, Zhiwei Hu, Leihao Lin, Jietao Lu, Liming Huang, Xuewu Zhu, Xiaoshu Teo, Chiahshean Lin, Lizhu |
author_sort | Xiao, Zhiwei |
collection | PubMed |
description | BACKGROUND: Chemotherapy-related fatigue (CRF) is a common symptom in non-small cell lung cancer (NSCLC) patients. A Chinese herbal formula cream for oral application, called Jianpishengsui (JPSS), is extensively used in the First Affiliated Hospital of Guangzhou University of Chinese Medicine as an internal preparation for CRF and is associated with a promising response. Due to the lack of high-quality clinical evidence, a randomized placebo-controlled trial is required to assess the efficacy and safety of JPSS. METHODS/DESIGN: The efficacy and safety of JPSS herbal formula cream will be evaluated through a prospective, randomized, placebo-controlled trial conducted in the First Affiliated Hospital of Guangzhou University of Chinese Medicine. NSCLC patients with CRF will be randomized into two groups at a ratio of 1:1. Each group will receive either 15 g of the oral JPSS herbal formula cream or placebo twice a day from day 6 to day 20 during two courses of paclitaxel + platinum/docetaxel + platinum/pemetrexed + platinum (TP/DP/AP) chemotherapy. The primary endpoint is the difference in the degree of fatigue between baseline (the day before the start of the intervention) and day 42, which will be assessed by the Revised Piper Fatigue Scale score. The secondary endpoints are quality of life (measured by the 43-item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Lung Cancer C43), Eastern Cooperative Oncology Group Performance Status, and Traditional Chinese Medicine syndrome score. The toxicity of the treatments will also be evaluated at the same time. All outcomes will be measured at baseline, day 6, day 21, and day 42 of the treatment. DISCUSSION: This randomized trial will investigate the efficacy and safety of JPSS applied for CRF in patients with NSCLC. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1900023451. Registered on 28 May 2019. |
format | Online Article Text |
id | pubmed-6966901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69669012020-01-27 Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial Xiao, Zhiwei Hu, Leihao Lin, Jietao Lu, Liming Huang, Xuewu Zhu, Xiaoshu Teo, Chiahshean Lin, Lizhu Trials Study Protocol BACKGROUND: Chemotherapy-related fatigue (CRF) is a common symptom in non-small cell lung cancer (NSCLC) patients. A Chinese herbal formula cream for oral application, called Jianpishengsui (JPSS), is extensively used in the First Affiliated Hospital of Guangzhou University of Chinese Medicine as an internal preparation for CRF and is associated with a promising response. Due to the lack of high-quality clinical evidence, a randomized placebo-controlled trial is required to assess the efficacy and safety of JPSS. METHODS/DESIGN: The efficacy and safety of JPSS herbal formula cream will be evaluated through a prospective, randomized, placebo-controlled trial conducted in the First Affiliated Hospital of Guangzhou University of Chinese Medicine. NSCLC patients with CRF will be randomized into two groups at a ratio of 1:1. Each group will receive either 15 g of the oral JPSS herbal formula cream or placebo twice a day from day 6 to day 20 during two courses of paclitaxel + platinum/docetaxel + platinum/pemetrexed + platinum (TP/DP/AP) chemotherapy. The primary endpoint is the difference in the degree of fatigue between baseline (the day before the start of the intervention) and day 42, which will be assessed by the Revised Piper Fatigue Scale score. The secondary endpoints are quality of life (measured by the 43-item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Lung Cancer C43), Eastern Cooperative Oncology Group Performance Status, and Traditional Chinese Medicine syndrome score. The toxicity of the treatments will also be evaluated at the same time. All outcomes will be measured at baseline, day 6, day 21, and day 42 of the treatment. DISCUSSION: This randomized trial will investigate the efficacy and safety of JPSS applied for CRF in patients with NSCLC. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1900023451. Registered on 28 May 2019. BioMed Central 2020-01-16 /pmc/articles/PMC6966901/ /pubmed/31948475 http://dx.doi.org/10.1186/s13063-019-3982-3 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Xiao, Zhiwei Hu, Leihao Lin, Jietao Lu, Liming Huang, Xuewu Zhu, Xiaoshu Teo, Chiahshean Lin, Lizhu Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial |
title | Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial |
title_full | Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial |
title_fullStr | Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial |
title_full_unstemmed | Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial |
title_short | Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial |
title_sort | efficacy and safety of jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966901/ https://www.ncbi.nlm.nih.gov/pubmed/31948475 http://dx.doi.org/10.1186/s13063-019-3982-3 |
work_keys_str_mv | AT xiaozhiwei efficacyandsafetyofjianpishengsuiforchemotherapyrelatedfatigueinpatientswithnonsmallcelllungcancerstudyprotocolforarandomizedplacebocontrolledclinicaltrial AT huleihao efficacyandsafetyofjianpishengsuiforchemotherapyrelatedfatigueinpatientswithnonsmallcelllungcancerstudyprotocolforarandomizedplacebocontrolledclinicaltrial AT linjietao efficacyandsafetyofjianpishengsuiforchemotherapyrelatedfatigueinpatientswithnonsmallcelllungcancerstudyprotocolforarandomizedplacebocontrolledclinicaltrial AT luliming efficacyandsafetyofjianpishengsuiforchemotherapyrelatedfatigueinpatientswithnonsmallcelllungcancerstudyprotocolforarandomizedplacebocontrolledclinicaltrial AT huangxuewu efficacyandsafetyofjianpishengsuiforchemotherapyrelatedfatigueinpatientswithnonsmallcelllungcancerstudyprotocolforarandomizedplacebocontrolledclinicaltrial AT zhuxiaoshu efficacyandsafetyofjianpishengsuiforchemotherapyrelatedfatigueinpatientswithnonsmallcelllungcancerstudyprotocolforarandomizedplacebocontrolledclinicaltrial AT teochiahshean efficacyandsafetyofjianpishengsuiforchemotherapyrelatedfatigueinpatientswithnonsmallcelllungcancerstudyprotocolforarandomizedplacebocontrolledclinicaltrial AT linlizhu efficacyandsafetyofjianpishengsuiforchemotherapyrelatedfatigueinpatientswithnonsmallcelllungcancerstudyprotocolforarandomizedplacebocontrolledclinicaltrial |